Maze Therapeutics, Inc. Common Stock (MAZE : NASDAQ)
Common Stock
$22.52
USD
-0.92 (-3.92%)
Last updated: 2026-09-18
Get MAZE alerts:
MAZE
Maze Therapeutics, Inc. Common Stock
WealthAwesomePerformance
1 Day
-3.92%
1 Week
-8.46%
1 Month
-24.30%
YTD
-9.34%
Key Statistics
Market Cap
$1.25B
52W High
$53.65
52W Low
$22.01
P/E Ratio
-
50 Day MA
$27.46
200 Day MA
$33.67
Beta
-
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/18/2026 | $23.27 | $23.57 | $22.01 | $22.52 | $22.52 | 1,494,800 |
| 9/17/2026 | $24.38 | $24.80 | $23.27 | $23.44 | $23.44 | 363,522 |
| 9/16/2026 | $24.33 | $24.72 | $23.74 | $23.91 | $23.91 | 385,672 |
| 9/15/2026 | $24.63 | $24.80 | $24.00 | $24.23 | $24.23 | 437,398 |
| 9/14/2026 | $24.90 | $25.85 | $24.46 | $24.67 | $24.67 | 589,283 |
| 9/11/2026 | $25.14 | $25.99 | $24.36 | $24.60 | $24.60 | 1,052,240 |
| 9/10/2026 | $24.26 | $25.62 | $23.94 | $24.82 | $24.82 | 1,181,300 |
| 9/9/2026 | $25.86 | $26.55 | $24.39 | $24.58 | $24.58 | 401,400 |
| 9/8/2026 | $25.76 | $26.57 | $25.30 | $26.37 | $26.37 | 365,300 |
| 9/4/2026 | $25.77 | $26.49 | $25.66 | $26.21 | $26.21 | 273,300 |
Analyst Price Targets
Based on 4 analysts covering MAZE · as of Sep 17, 2026
Wall Street analysts forecast MAZE stock price to rise 177.7% over the next 12 months.
Consensus
Strong Buy4.75 / 5.00
Avg. Target
US$62.55
+177.7% Upside
Current Price
US$22.52
Last close
Analyst Breakdown (4 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MAZE's historical volatility
30-Day Vol
41.0%
Annualized
90-Day Vol
46.0%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$18.84
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$21.22 | US$18.42 – US$24.44 |
| 60 trading days | US$19.99 | US$16.37 – US$24.42 |
| 90 trading days | US$18.84 | US$14.74 – US$24.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Financials
- Revenue (TTM)
- $20.00M
- EBITDA
- $-143.71M
- Profit Margin
- 0.00%
- ROE (TTM)
- -37.35%
- EPS (Diluted)
- -2.44
- Book Value
- 8.16
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About MAZE.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| IMCC | Im Cannabis Corp | $4.23 | +143.10% |
| QNME | Quanome Technologies, Inc. | $0.56 | +92.15% |
| REFR | Research Frontiers Incorporated | $0.65 | +68.13% |
| GIPR | Generation Income Properties Inc | $0.72 | +63.37% |
| MRNO | Murano Global Investments PLC Ordinary Shares | $0.34 | +56.89% |
| TJGC | TJGC Group Limited | $16.84 | +52.95% |
| NBRGR | Newbridge Acquisition Limited Rights | $0.36 | +51.44% |
| ZTG | Zenta Group Company Limited | $1.81 | +50.83% |